CASE REPORT:

Acute Respiratory Distress Syndrome and septic shock in pregnant woman with COVID-19

Jesselyn Kristanti1*, Fransiscus OH Prasetyadi2

1Emergency Department, Dr Ramelan Naval Hospital, Surabaya, Indonesia, 2Obstetrics and Gynecology Department, Dr Ramelan Naval Hospital, Surabaya, Indonesia

ABSTRACT

Objectives: To prove that pregnancy do not worsen the clinical course of COVID-19 compared with nonpregnant individuals as found in the first case of COVID-19 pregnant woman died in our center.

Case Report: A 27-year-old female, G2P0A1 23/24 weeks without comorbidities, complaint of diarrhea and 4 days later got fever, cough, and dyspnea. She was referred to our hospital for further evaluation because of deterioration. SARS CoV-2 RT-PCR tested positive. Blood, sputum, and urine cultures tested negative. She was intubated and given LMWH. She was worsened rapidly despite being on intensive care for 3 days with last vital signs recorded: blood pressure 66/24 mmHg with vasopressors, heart rate 136 beats/minutes, temperature 41°C, oxygen saturation 62%, cardiac arrest and expired.

Conclusion: COVID-19 pregnant women need proper care so that they will not fall into conditions such as ARDS and septic shock. Close monitoring on clinical and laboratory course is recommended. We suggest clinicians to be aware so as rapid deterioration and death can be avoided.

Keywords: COVID-19; pregnant woman; ARDS; septic shock

ABSTRAK


Kata kunci: COVID-19; wanita hamil; ARDS; syok septik

*Correspondence: Jesselyn Kristanti, Emergency Department, Dr Ramelan Naval Hospital, Surabaya, Indonesia. E-mail: fjesselynkristanti@gmail.com
INTRODUCTION

Coronavirus disease 2019 (COVID-19), a disease caused by SARS-CoV-2, a newly emergent coronavirus, was firstly identified in Wuhan, China, in December 2019. Epidemiology and virologic studies suggest that transmission mainly occurs from symptomatic people to others by close contact through respiratory droplets, by direct contact with infected persons, or by contact with contaminated objects and surfaces. Available data from multiple small series and case reports, do not raise the risk of SARS-CoV-2 infection, do not exacerbate the clinical course of COVID-19 as compared to nonpregnant individuals of the same age, and most (>90 percent) infected mothers recover without giving birth. In the medical literature, many maternal deaths due to cardio-pulmonary complications, including multiorgan failure, have been recorded. Most of these women were generally healthy prior to the SARS-CoV-2 infection. This is the first death case of a pregnant woman with COVID-19 in our hospital, specifically a severe one with complications of acute respiratory distress syndrome (ARDS) and septic shock. A permission had been obtained to report this case.

CASE REPORT

This case study reported the circumstances surrounding a pregnant woman who contracted COVID-19 and died as a result of her illness. We presented a case of a 27-year-old female in her second pregnancy at 23/24 weeks gestation with a history of miscarriage on her first pregnancy in October 2019. We did history taking with her husband, he stated that she has been admitted to the previous hospital for 1 week with chief complaint of diarrhea prior to admission, and four days after she was admitted she got additional complaints of fever, cough, and dyspnea and was moved to isolation ward. She did not have any history of hypertension, diabetes, obesity, alcohol use, drug use, or other significant comorbidities. She was referred to our hospital for further management and evaluation because of deterioration. Her RT-PCR swab for SARS-CoV-2 was positive; with blood, sputum, and urine cultures result tests are negative. Due to severe acute respiratory distress syndrome she was intubated and put under mechanical ventilation. She was given azithromycin 500 mg iv qd, chloroquine phosphate 500 mg po bid, oseltamivir 75 mg po bid, vitamin C 1 gram iv qd, other than that she was given low molecular weight heparin (enoxaparin 0.4 ml sc qd). She was worsened rapidly despite being on intensive care for 3 days with last vital signs recorded: blood pressure was 66/24 mmHg with vasopressors, heart rate was 136 beats/minute, temperature 41°C, oxygen saturation 62% on ventilator. Finally, due to this rapid deterioration, she was on cardiac arrest and expired following unsuccessful cardiopulmonary resuscitative efforts.

DISCUSSION

This patient first came with a chief complaint of gastrointestinal symptom (diarrhea) which has been reported in some medical literatures as a possible presenting complaint of COVID-19. Since accumulated evidence supports SARS-CoV-2 transmission via feces, suspected COVID-19 patients with GI symptoms such as nausea, vomiting, and diarrhea should be seriously considered. Four days later she was complaining of fever, cough, and shortness of breath which were the most emphasized symptoms of COVID-19.

Pregnancy and childbirth, according to available evidence from several small series and case reports, do not raise the risk of SARS-CoV-2 infection, do not exacerbate the clinical course of COVID-19 when compared to nonpregnant individuals of the same age, and most (>90 percent) infected mothers recover without giving birth. Older adults, especially those with comorbidities, are those demographically most affected by serious disease, and most pregnant women are younger than middle age; however, they may have comorbid conditions that increase their risk (eg, obesity, diabetes).

It is known that some patients with severe COVID-19 have laboratory evidence of an exuberant inflammatory response (similar to cytokine release syndrome), which has been associated with critical and fatal illnesses. It is unclear if pregnancy's normal immunologic changes
influence the occurrence and course of this response. Symptomatic infection can range from mild to critical disease. As for this patient, based on WHO Interim Guidance on Clinical Management of COVID-19 which was published on 27 May 2020, from the COVID-19 disease severity, criteria of critical disease which is severe acute respiratory distress syndrome, sepsis and septic shock is obtained. Severe COVID-19 patients are often managed in the prone position in the ICU. While even a semi-prone position can be difficult to place a pregnant woman in the last half of pregnancy, some ICUs have applied this approach to pregnant women, and so did in this patient.

This patient was given low molecular weight heparin (enoxaparin). We have learned that coagulopathy is common in patients with severe COVID-19, and both venous and arterial thromboembolism have been reported so that per WHO recommendation a prophylaxis should been given.

An antiviral agent, Remdesivir, is a treatment for COVID-19 which resulted in faster time to recovery. Remdesivir is a novel nucleotide analogue that has activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in vitro. It was not given to this patient as the medication unfortunately is not yet available in our country.

Convalescent plasma which may possible in providing clinical benefit was not given because it is too, not yet available in our hospital by the time the patient was admitted. However, according to a recent randomized controlled trial, convalescent plasma therapy applied to standard treatment did not result in a statistically significant increase in time to clinical improvement within 28 days for patients with serious or life-threatening COVID-19, as compared to standard treatment alone. Early termination of the experiment, which may have been underpowered to identify a clinically significant difference, has limited the interpretation.

**CONCLUSION**

We report herein the first maternal death in our hospital due to COVID-19. Pregnant women with COVID-19 need proper care so that they will not fall into critical conditions such as ARDS and septic shock. Close monitoring on clinical and laboratory courses is recommended. We suggest clinicians that it is prudent to be aware of the potential of rapid deterioration and maternal death among pregnant women diagnosed with COVID-19 despite knowing that information about COVID-19 and its management including specific therapy is still evolving rapidly, and interim guidance by multiple organizations is constantly being updated and expanded.

**ACKNOWLEDGMENT**

We thank Dr Ramelan Naval Hospital staffs for their efforts to deal with COVID-19. We also thank the Almighty God for reasons too numerous to mention. We declare no competing interests.

**REFERENCES**


